A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma

Altendorf-Hofmann, A.; Scheele, J.

doi:10.1016/s1055-3207(02)00091-1

Cited by 166 publications

(125 citation statements)

References 100 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…The spreading of cells from the primary lesion to a secondary organ and the subsequent development of distant metastases is a key factor that limits patient survival rate. This remains one of the most complex issues faced in medicine (2).…”

Section: Introductionmentioning

confidence: 99%

Role of liver ICAM-1 in metastasis

2017

View full text Add to dashboard Cite

Abstract. Intercellular adhesion molecule (ICAM)-1, is a transmembrane glycoprotein of the immunoglobulin (Ig)-like superfamily, consisting of five extracellular Ig-like domains, a transmembrane domain and a short cytoplasmic tail. ICAM-1 is expressed in various cell types, including endothelial cells and leukocytes, and is involved in several physiological processes. Furthermore, it has additionally been reported to be expressed in various cancer cells, including melanoma, colorectal cancer and lymphoma. The majority of studies to date have focused on the expression of the ICAM-1 on the surface of tumor cells, without research into ICAM-1 expression at sites of metastasis. Cancer cells frequently metastasize to the liver, due to its unique physiology and specialized liver sinusoid capillary network. Liver sinusoidal endothelial cells constitutively express ICAM-1, which is upregulated under inflammatory conditions. Furthermore, liver ICAM-1 may be important during the development of liver metastasis. Therefore, it is necessary to improve the understanding of the mechanisms mediated by this adhesion molecule in order to develop host-directed anticancer therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of liver ICAM-1 in metastasis

2017

View full text Add to dashboard Cite

show abstract

“…Liver metastases can be resected with curative intent; however, the probability of achieving a cure is dependent on the number of tumor nodules and the disease-free interval. 16,17 Curative surgical resection is unlikely among patients with multiple (44) tumor nodules and less than 5-10% of patients who present with metastatic colorectal cancer are candidates for curative surgery. Currently, the 5-year survival after curative liver resection for colorectal metastases is 25-35%, depending on various risk factors.…”

mentioning

confidence: 99%

“…Currently, the 5-year survival after curative liver resection for colorectal metastases is 25-35%, depending on various risk factors. [17][18][19] Systemic and intrahepatic administration of chemotherapy has been used to reduce the recurrence rates for following surgical resection, but the overall improvement in median survival with these approaches has been modest. [19][20][21] We conducted phase I/II studies of Onyx-015, an oncolytic adenovirus attenuated due to deletion of the viral E1b 55k gene.…”

mentioning

confidence: 99%

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin

Reid

Freeman²,

Post³

et al. 2005

Cancer Gene Ther

View full text Add to dashboard Cite

“…Pre-operative imaging techniques, patient selection, surgical techniques, postoperative care and new cytotoxic and biologic agents for preoperative and post-operative treatment have dramatically improved the resectability rate of liver metastases. The old criteria for resectability of CLM have accordingly changed: number of metastases is not a risk factor for survival whenever a R0 resection (complete resection with no microscopic residual tumour) is achieved [127] . In spite of some conflicting reports, evidence shows that size is not a resectability factor, but a factor related to the aggressiveness of the tumour.…”

Section: Resectabilitymentioning

confidence: 99%

Metastatic lesions to the liver: Surgical indications and techniques

Tejedor¹,

Serrablo²

2013

JST

View full text Add to dashboard Cite

Background: Although there is an established agreement on the advantage of liver resection for metastatic colorectal and neuroendocrine tumours, the role of hepatic surgery in patients with liver metastases from non-colorectal and non-neuroendocrine carcinoma is not well defined. In recent years, despite the poor results, liver metastases suitable for surgery have been treated with resection. The results reported in recent studies support a developing trend toward surgery in this setting. Also, as there are no data that in fact suggest the utility of alternative treatments for these lesions, the role of surgery is reinforced. Methods:A systematic search of English and non-English literature using MEDLINE on the outcomes of patients after surgical treatment of liver metastases from different solid tumours was undertaken. A summary of current surgical techniques used to improve their resectability has been added.Results: All papers reporting median survival and 5-year survival have been selected and presented in tables for most of the primary tumours reviewed. Conclusions:Apart from patients with colorectal and neuroendocrine tumours, liver resection may offer a significative survival advantage in selected patients, mainly those with metastases coming from breast, gastrointestinal stromal tumours, testis, ovary and kidney.

show abstract

A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma

Cited by 166 publications

References 100 publications

Role of liver ICAM-1 in metastasis

Role of liver ICAM-1 in metastasis

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin

Metastatic lesions to the liver: Surgical indications and techniques

Contact Info

Product

Resources

About